FDA panel backs gene therapy for rare form of blindness

Read Time:24 Second

Spark Therapeutics Inc’s experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease. The panel voted unanimously in favor of the treatment, Luxturna, which is designed to treat inherited retinal diseases caused by defects in a gene known as RPE65, which tells cells to produce an enzyme critical to normal vision.

About Post Author

A warsame

Published by A Warsame is senior Editor and managing Director of Mareeg Media Whatup :+447737886245
Happy
Happy
0 0 %
Sad
Sad
0 0 %
Excited
Excited
0 0 %
Sleepy
Sleepy
0 0 %
Angry
Angry
0 0 %
Surprise
Surprise
0 0 %